ライフサイエンスコーパス: bone mineral

1 entration in bone increased by 0.39 mug Gd/g bone mineral +/- 0.14 per 1 mL of GBCA administered.

2 an in control subjects (mean, -1.06 mug Gd/g bone mineral +/- 0.71) (P = .01).

3 her in exposed subjects (mean, 1.19 mug Gd/g bone mineral +/- 0.73 [standard deviation]) than in cont

4 ood interventions generally had no effect on bone mineral acquisition or body composition either with

5 en, is the aggressive and persistent loss of bone mineral and structural elements leading to loss of

6 Bone minerals are acquired during growth and are key det

7 P), biphasic calcium phosphate (BCP), bovine bone mineral (BBM) or blood clot.

8 Bone mineral content (BMC) and bone mineral density (BMD

9 at ages 6, 14, 17, and 20 y, and whole-body bone mineral content (BMC) and bone mineral density (BMD

10 total femur, femoral neck, and lumbar spine bone mineral content (BMC) and bone mineral density (BMD

11 ential nutrients that are needed to increase bone mineral content (BMC) and potentially decrease frac

12 n D during pregnancy have greater whole-body bone mineral content (BMC) at birth than those of mother

13 rtical midshaft morphometric properties, and bone mineral content (BMC) in 40 different regions of th

14 h bone mineral density (BMD), bone area, and bone mineral content (BMC) in a cohort of young adults.

15 f whole-body (WB) and skeletal site-specific bone mineral content (BMC) relative to linear growth in

16 Bone mineral density (BMD) and bone mineral content (BMC) Z scores were significantly l

17 de association study of areal BMD (aBMD) and bone mineral content (BMC) Z-scores measured by dual ene

18 pring total body bone mineral density (BMD), bone mineral content (BMC), and bone area (BA) were meas

19 bgroup at 2 y of age : Bone mineral density, bone mineral content (BMC), area-adjusted BMC, and bone

20 cle strength, lean mass (LM), fat mass (FM), bone mineral content (BMC), muscle cross-sectional area

21 sis) and 14% (diaphysis) sites of the tibia, bone mineral content (BMC), volumetric bone mineral dens

22 dy, BV/TV%, proximal femur and hemi-mandible bone mineral content and bone mineral density, and trabe

23 rged the radio-opaque area and increased the bone mineral content and density in the radiological ana

24 assessed every 6 mo included the total-body bone mineral content and density, cortical and trabecula

25 rolone improves lean body mass accretion and bone mineral content and that the administration of the

26 wever, the MRD increased anxiety and reduced bone mineral content in both I278T mice and wild-type co

27 Bone mineral content measured by DXA, total body water b

28 ignificantly increased bone mineral density, bone mineral content, and bone area per tissue area.

29 composition, including fat mass, lean mass, bone mineral content, and bone mineral density, was dete

30 d2 for several T cell measures and Prkca for bone mineral content.

31 appendicular lean mass (skeletal muscle) and bone mineral content; and higher plasma insulin and trig

32 Similarly, changes in spine and femoral neck bone mineral contents (BMCs) were not significantly diff

33 Deproteinized bovine bone mineral (DBBM) has been extensively studied and use

34 ra-oral approach, where deproteinized bovine bone mineral (DBBM) particles were placed contralaterall

35 surface then a layer of deproteinized bovine bone mineral (DBBM) was added.

36 DXA (reference standard) to determine areal bone mineral densities (BMDs), and (c) quantitative CT w

37 A significant decrease in global trabecular bone mineral density (38.1%) and cortical thickness (13.

38 Although areal bone mineral density (aBMD) assessed by dual-energy x-ra

39 trations of several PFASs and measured areal bone mineral density (aBMD) by dual-energy X-ray absorpt

40 are variables that are not captured by areal bone mineral density (aBMD), and dietary protein intakes

41 Condylar bone mineral density (BMD) (computed tomography Hounsfie

42 in Z mRNA level strongly correlated with low bone mineral density (BMD) (g/cm(2)), lumbar spine L2-L4

43 We searched for variants associated with bone mineral density (BMD) after enriching the discovery

44 oporosis is a condition characterized by low bone mineral density (BMD) and an increased risk of frac

45 n about the effects of eradication of HCV on bone mineral density (BMD) and biomarkers of bone remode

46 Bone mineral density (BMD) and bone mineral content (BMC

47 ody mass, shortened body length, and reduced bone mineral density (BMD) and content (BMC) first evide

48 Trabecular and cortical bone mineral density (BMD) and content were assessed at

49 of soft-tissue parameters were compared with bone mineral density (BMD) and cortical bone thickness.

50 c skeletal disorder characterized by reduced bone mineral density (BMD) and disrupted bone architectu

51 using computed tomography thoracic vertebral bone mineral density (BMD) and fracture prevalence among

52 ociation studies (GWASs) identified multiple bone mineral density (BMD) and fracture-associated loci.

53 hoblastic leukemia (ALL) are at risk for low bone mineral density (BMD) and frail health, outcomes po

54 have increased fracture risk, despite normal bone mineral density (BMD) and high BMI-factors that are

55 tary patterns that explain most variation in bone mineral density (BMD) and hip bone geometry are ass

56 tis C virus (HCV) is associated with reduced bone mineral density (BMD) and increased fracture rates,

57 g CAC progression, including measurements of bone mineral density (BMD) and novel bone markers in adu

58 The association between low bone mineral density (BMD) and periodontitis in perimeno

59 Whether PM is associated with loss of bone mineral density (BMD) and risk of bone fractures is

60 Children with cancer may develop low bone mineral density (BMD) any time before or after diag

61 Bone mineral content (BMC) and bone mineral density (BMD) are positively correlated wit

62 one density contributing to lower volumetric bone mineral density (BMD) at both distal radius and tib

63 tion values across all adult ages to measure bone mineral density (BMD) at routine CT.

64 hip, and non-vertebral fractures as well as bone mineral density (BMD) at the lumbar spine, total hi

65 ce imaging in 215 healthy army recruits, and bone mineral density (BMD) by Dual X-Ray Absorptiometry

66 Changes in bone turnover markers, bone mineral density (BMD) by dual-energy x-ray absorpti

67 Derangement in bone mineral density (BMD) caused by glucocorticoid is w

68 Bone mineral density (BMD) changes and fracture rate.

69 We compared adjusted bone mineral density (BMD) changes between human immunod

70 ave a protective effect on lumbar spine (LS) bone mineral density (BMD) compared with lower protein i

71 Background Bone mineral density (BMD) could be derived from CT loca

72 Bone mineral density (BMD) derived from cardiac CT may b

73 Little is known about bone mineral density (BMD) during pregnancy.

74 s-seronegative men aged 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil f

75 endpoint was percentage change in total hip bone mineral density (BMD) from baseline to week 48 in t

76 g the effect of vitamin D supplementation on bone mineral density (BMD) have yielded conflicting resu

77 genetic risk factors (GRFs) for fracture and bone mineral density (BMD) identified from people of Eur

78 an mass (ALM), quadriceps strength (QS), and bone mineral density (BMD) in 2986 men and women, aged 1

79 leotide polymorphisms (SNPs) associated with bone mineral density (BMD) in adults.

80 nonalcoholic fatty liver disease (NAFLD) and bone mineral density (BMD) in children or adolescents, b

81 ine the effect of calcium supplementation on bone mineral density (BMD) in lactating women.

82 Weight loss (WL) negatively affects bone mineral density (BMD) in older populations and has

83 We aimed to evaluate bone mineral density (BMD) in patients with scoliosis by

84 (FES) standing system for rehabilitation of bone mineral density (BMD) in people with Spinal Cord In

85 in osteoprotegerin correlate with decreased bone mineral density (BMD) in untreated HIV infection.

86 monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with postmenopausal

87 Background: Bone mineral density (BMD) is a heritable phenotype that

88 Background: Whether change in bone mineral density (BMD) is an accurate indicator of a

89 High bone mineral density (BMD) is associated with an increas

90 [control (CON)].RCE significantly attenuated bone mineral density (BMD) loss at the L2-L4 lumbar spin

91 -analysis examining isoflavone therapies and bone mineral density (BMD) loss in peri- and postmenopau

92 eficiency virus (HIV) infection and with low bone mineral density (BMD) may be at higher risk of oste

93 ted (PHIV) children and adolescents with low bone mineral density (BMD) may be at higher risk of oste

94 Bone mineral density (BMD) measured by dual-energy x-ray

95 Bone mineral density (BMD) measurement by dual-energy x-

96 titative ultrasonography (QUS) in predicting bone mineral density (BMD) reduction in a population of

97 g-reported parental hip fracture in a unique bone mineral density (BMD) registry linked to administra

98 sulting in larger increases in hip and spine bone mineral density (BMD) than with either drug alone.

99 diac CT can be used to help measure thoracic bone mineral density (BMD) to identify individuals who h

100 lumbar spine bone mineral content (BMC) and bone mineral density (BMD) was assessed using DXA.

101 Bone mineral density (BMD) was measured using DXA.

102 nd whole-body bone mineral content (BMC) and bone mineral density (BMD) were measured at age 20 y thr

103 Plasma bone turnover markers and bone mineral density (BMD) were performed at weeks 0, 12

104 Plasma bone turnover markers and bone mineral density (BMD) were quantified at weeks 0, 1

105 ated deficiencies and cardiovascular health, bone mineral density (BMD), and physical fitness.

106 ally relevant to osteoporosis, assessed from bone mineral density (BMD), as a new potential target of

107 content and density, cortical and trabecular bone mineral density (BMD), BMC, and bone area at the 4%

108 stigated their prospective associations with bone mineral density (BMD), bone area, and bone mineral

109 ions between changes in areal and volumetric bone mineral density (BMD), bone microstructure and stre

110 Offspring total body bone mineral density (BMD), bone mineral content (BMC),

111 by ultrasound examination; bone retraction, bone mineral density (BMD), bone volume/tissue volume (B

112 red genetic signals robustly associated with bone mineral density (BMD), but not the precise localiza

113 o, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in pat

114 ootball after 6 months, hip and lumbar spine bone mineral density (BMD), mental health score, fat and

115 orted that geographical variation influences bone mineral density (BMD), obesity, and sarcopenia rela

116 ions aimed at preventing fracture, improving bone mineral density (BMD), or preventing or delaying os

117 the patients showed an increase in fitness, bone mineral density (BMD), quality of life and a decrea

118 tion between B-vitamin status biomarkers and bone mineral density (BMD), risk of osteoporosis, and bi

119 bl-Wnt16 mice displayed increased total body bone mineral density (BMD), surprisingly caused mainly b

120 were accompanied by diminishing weight loss, bone mineral density (BMD), trabecular thickness, trabec

121 soprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium abso

122 S dataset from subjects with low versus high bone mineral density (BMD), we recovered methylation val

123 However, obese people have a higher bone mineral density (BMD), which suggests that low 25(O

124 The primary outcome was total hip bone mineral density (BMD), with femoral neck BMD, lumba

125 The reference standard was a bone mineral density (BMD)-based Fracture Risk Assessmen

126 e-wide association study summary datasets of bone mineral density (BMD).

127 isease diagnosed primarily by measurement of bone mineral density (BMD).

128 linically relevant, significant decreases in bone mineral density (BMD).

129 elationship of those variables to changes in bone mineral density (BMD).

130 ide association studies are also involved in bone mineral density (BMD).

131 nfection is associated with 2% to 6% loss of bone mineral density (BMD).

132 useful tools to screen for reduced skeletal bone mineral density (BMD).

133 LS)-, total hip (HIP)- and femoral neck (FN)-bone mineral density (BMD).

134 ng-related disease diagnosed primarily using bone mineral density (BMD).

135 -wide association study (GWAS) for estimated bone mineral density (eBMD) identified 1103 independent

136 y lean mass (TB-LM) and total-body less head bone mineral density (TBLH-BMD) regions in 10,414 childr

137 ct of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth.

138 Bone mineral density after reaching skeletal maturity is

139 Of six adults that were subjected to bone mineral density analysis, three presented with oste

140 eal (P=0.001) and volumetric (P<0.001-0.006) bone mineral density and 1.5- to 1.8-fold increases in r

141 Canagliflozin is associated with decreased bone mineral density and a potential increased risk for

142 Bone mineral density and abdominal fat and paraspinal mu

143 Alveolar bone mineral density and alveolar bone volume were quant

144 ghly prevalent disorder characterized by low bone mineral density and an increased risk of fracture,

145 with or without potassium citrate had higher bone mineral density and better mechanical properties th

146 r alafenamide had more favourable effects on bone mineral density and biomarkers of renal safety than

147 ation and finite element analysis to measure bone mineral density and bone strength at the hip and sp

148 osure to 20 mg/kg fluoxetine reduced femoral bone mineral density and bone volume fraction, negativel

149 I) is a genetic disorder that results in low bone mineral density and brittle bones.

150 inflammation was associated with declines in bone mineral density and cancellous bone volume.

151 ascular volume, type H vessel formation, and bone mineral density and contents, as well as BV/TV, Tb.

152 Conclusion In addition to bone mineral density and geometry of the proximal femur,

153 Hip and spine bone mineral density and glomerular filtration were each

154 Patients with type 1 diabetes have lower bone mineral density and higher risk of fractures.

155 Patients also suffer from decreased bone mineral density and increased fracture risk.

156 g from autism have been reported to have low bone mineral density and increased risk for fracture, ye

157 genetic factors with pleiotropic effects on bone mineral density and lean mass.Bone mineral density

158 ffects on bone mineral density and lean mass.Bone mineral density and lean skeletal mass are heritabl

159 mine if computed tomographic (CT) metrics of bone mineral density and muscle mass can improve the pre

160 L5HU and PsoasL4-5, which are surrogates for bone mineral density and muscle mass, respectively, were

161 ignificantly higher bone volume/total volume bone mineral density and number of osteoblasts in the ra

162 We prespecified six secondary bone mineral density and renal biomarker safety endpoint

163 disoproxil fumarate in all six prespecified bone mineral density and renal biomarker safety endpoint

164 nce of viral suppression and led to improved bone mineral density and renal function.

165 In this population-based cohort study, bone mineral density and risk factors were used to calcu

166 Osteopenia, osteoporosis, and low bone mineral density are frequent in patients with HIV.

167 ithms that combine clinical risk factors and bone mineral density are now widely used in clinical pra

168 of a CpG site proximal to the NFIX locus and bone mineral density at age 17.

169 mide had a significantly smaller decrease in bone mineral density at hip (mean change -0.10% [95% CI

170 01), and a significantly smaller decrease in bone mineral density at spine (mean % change -1.30 vs -2

171 , vs. 55.0 to 52.3 kg [5% decrease]), as did bone mineral density at the total hip (grams per square

172 ciation between serum PFAS concentration and bone mineral density at total femur (TFBMD), femoral nec

173 rnib monotherapy treatment reveal additional bone mineral density benefit but likely no added cardiov

174 d a smaller decrease in lumbar spine and hip bone mineral density but greater accumulation of limb an

175 micro-computed tomographic (CT) imaging and bone mineral density by peripheral quantitative CT scann

176 articipants were stratified by spine and hip bone mineral density categories.

177 absorptiometry (DEXA) was used to determine bone mineral density changes in TDF-exposed patients.

178 nce of pathogenic variants in RECQL4 and low bone mineral density correlate with the history of incre

179 We also apply our approach to bone mineral density data, and again final models contai

180 The local trabecular bone mineral density decreased in both high stress and l

181 Bone mineral density decreased in the first 6 months, wi

182 There were no bone architectural or bone mineral density differences by microCT.

183 models, I(1670)/I(1640,) age, and volumetric bone mineral density explained 50.2% (microscope) and 49

184 her fracture genetic risk score (Fx-GRS) and bone mineral density genetic risk score (BMD-GRS) modify

185 er group; we instead observed an increase of bone mineral density in both lumbar spine and total hip

186 ations in Col6a5 that underlies variation in bone mineral density in both mouse and human.

187 ested a trend of less vertical bone gain and bone mineral density in controls (P >0.05).

188 sing and has been linked to both obesity and bone mineral density in humans by genome-wide associatio

189 restores reproductive capacity and increases bone mineral density in patients with hypothalamic ameno

190 tch study, we aimed to assess the changes in bone mineral density in postmenopausal osteoporotic wome

191 ous work has shown that odanacatib increases bone mineral density in postmenopausal women with low bo

192 ze that an observed decrease in genetic heel bone mineral density in the Neolithic reflects adaptatio

193 48 months, the primary outcome of mean spine bone mineral density increased by 18.3% (95% CI 14.9-21.

194 Similarly, femoral neck bone mineral density increased more in the teriparatide

195 ineral density secondary outcomes, total hip bone mineral density increased more in the teriparatide

196 ion Combined assessment of bone strength and bone mineral density is a cost-effective strategy for os

197 Low bone mineral density is an independent and significant p

198 Systemic and persistent low bone mineral density is an independent prognostic factor

199 uce fragility fractures in patients with low bone mineral density is beyond the scope of the guidelin

200 ar growth attenuation and adverse effects on bone mineral density is generally low but should be cons

201 Bone mineral density is known to be a heritable, polygen

202 The pathogenesis of declining bone mineral density is poorly understood but it is inhe

203 s in eight loci, including seven established bone mineral density loci: WNT4, GALNT3, MEPE, CPED1/WNT

204 y, whereas ST-SPI diet only reduced cortical bone mineral density loss 3 wk post-OVX.

205 efficacy but with decreased renal injury and bone mineral density loss compared with TDF.

206 Total hip bone mineral density loss was similarly greater at week

207 ogesterone acetate (DMPA) is associated with bone mineral density loss.

208 nclusion Experimental evidence suggests that bone mineral density measurements are accurate and preci

209 We aimed to investigate the effect on bone mineral density of switching from a regimen contain

210 e revealed increased remodelling and reduced bone mineral density portrayed by increased carbonate to

211 For the bone mineral density secondary outcomes, total hip bone

212 Lumbar spine bone mineral density showed a mean increase by day 85 an

213 risk factors for osteoporotic fractures, and bone mineral density surveillance) originated from the q

214 e status, previous tamoxifen use, and lowest bone mineral density T score in the lumbosacral spine, t

215 commended in postmenopausal women who have a bone mineral density T score of -2.5 or less, a history

216 erate or one severe vertebral fracture and a bone mineral density T score of less than or equal to -1

217 For bone mineral density T scores at the femoral neck, biome

218 rs or more, with a femoral neck or total hip bone mineral density T-score between -2.5 and -4.0 if no

219 otic fracture, the clinician should obtain a bone mineral density test.

220 s associated with significantly less loss of bone mineral density than a standard regimen containing

221 urgery, the hind limb had significantly less bone mineral density than contralateral controls, confir

222 pids, and greater decreases from baseline in bone mineral density than did those who received placebo

223 ficantly smaller mean percentage declines in bone mineral density than those receiving tenofovir diso

224 d contributions to local processes including bone mineral density through candidate genes such as ost

225 p<0.0001), and mean percentage change in hip bone mineral density was 1.33% (2.20) in the elvitegravi

226 week 48, the mean percentage change in spine bone mineral density was 2.24% (SD 3.27) in the elvitegr

227 Normal bone mineral density was detected in 2/8 case, osteopeni

228 Bone mineral density was measured at lumbar spine and th

229 Concomitantly, alveolar bone mineral density was significantly lower in all thre

230 Total and trabecular bone mineral density were significantly lower (-13.4% an

231 ce at routine CT to identify adults with low bone mineral density who are at risk for osteoporosis.

232 ge from baseline to week 48 in spine and hip bone mineral density with a null hypothesis of zero betw

233 Mean bone mineral density z scores (lumbar spine and femur) r

234 after treatment started (including data for bone mineral density).

235 ructure after 12 weeks follow-up covered the bone mineral density, -volume, -trabecular thickness and

236 The pathogenesis of declining bone mineral density, a universal feature of ageing, is

237 Bone mineral density, abdominal fat area, and paraspinal

238 osterone had beneficial effects on increased bone mineral density, and decreased body fat; adverse ef

239 ice by adoptive transfer, and bone turnover, bone mineral density, and indices of bone structure and

240 howed a reduction of trabecular bone volume, bone mineral density, and number and thickness in KO mic

241 Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the U.S. popul

242 in other frailty measures, body composition, bone mineral density, and physical functions.

243 r and hemi-mandible bone mineral content and bone mineral density, and trabeculae number were similar

244 ne strength (indicated by fracture and lower bone mineral density, BMD) is associated with subsistenc

245 1 y of age and in a subgroup at 2 y of age : Bone mineral density, bone mineral content (BMC), area-a

246 Spinal loading significantly increased bone mineral density, bone mineral content, and bone are

247 p-null (Bsp(-/-)) mice exhibit reductions in bone mineral density, bone turnover, osteoclast activati

248 ances (PFASs) has been associated with lower bone mineral density, but data are limited, particularly

249 tients with chronic hepatitis B have reduced bone mineral density, but the reduction is limited to 1

250 ect to their metabolic bone status including bone mineral density, calcium kinetics studies, and mark

251 nes were significantly associated with spine bone mineral density, including BDNF, PDE4D, and SATB2,

252 ovements in blood pressure, body mass index, bone mineral density, lipid levels, or quality-of-life m

253 Clinical and laboratory parameters, bone mineral density, microarchitecture, and vertebral f

254 splay skeletal alterations including reduced bone mineral density, modified bone structure and distin

255 Other than increased bone mineral density, no improvement rates exceeded thos

256 Notably, bone mineral density, osteoporosis and osteoporotic frac

257 The significantly improved bone mineral density, overall safety, and efficacy data

258 Despite normal to high bone mineral density, patients with type 2 diabetes (T2D

259 we show that Ppia(-/-) mice demonstrate low bone mineral density, reduced osteoblast numbers, and in

260 ibia, bone mineral content (BMC), volumetric bone mineral density, robustness, and strength indexes w

261 users should not routinely screen or monitor bone mineral density, serum creatinine, magnesium, or vi

262 ostin inhibition could be applied to enhance bone mineral density, stability, and regeneration in non

263 eplacement therapy has been shown to improve bone mineral density, studies have also linked bone loss

264 n increases in bone formation biomarkers and bone mineral density, suggesting that sclerostin inhibit

265 ng bone disease that is characterised by low bone mineral density, typically assessed using dual-ener

266 oncentration, serum phosphate concentration, bone mineral density, vascular calcification, renal func

267 These groups exhibited decreased bone mineral density, volume fraction, and bone formatio

268 t mass, lean mass, bone mineral content, and bone mineral density, was determined by dual-energy X-ra

269 rial which tested the effect of denosumab on bone mineral density, we assessed the impact of this dru

270 Texture parameters, but not bone mineral density, were associated with lowest lifeti

271 effects of elagolix, especially decreases in bone mineral density, were attenuated with add-back ther

272 the loss of total, trabecular, and cortical bone mineral density, whereas ST-SPI diet only reduced c

273 AS concentrations were associated with lower bone mineral density, which varied according to the spec

274 at individuals with RTS have decreased areal bone mineral density.

275 ea, but there were no such associations with bone mineral density.

276 sa that is independent of that provided with bone mineral density.

277 e surface, accompanied by a dramatic loss of bone mineral density.

278 ut not CD8+ T cells significantly diminished bone mineral density.

279 ears in a Women's Health Initiative study of bone mineral density.

280 n associated with renal toxicity and reduced bone mineral density.

281 libido, vasomotor instability, and decreased bone mineral density.

282 ion, and then develop anemia and a decreased bone mineral density.

283 omy-induced osteoporosis results in improved bone mineral density.

284 exposure were independent predictors of low bone mineral density.

285 evious aromatase inhibitor use, and baseline bone mineral density.

286 r trabecular number, connective density, and bone mineral density.

287 nd was associated with a smaller decrease in bone mineral density; however, greater resistance and ga

288 with a significant increase in femoral neck bone mineral density; vascular calcification remained un

289 Individuals who share the same bone-mineral density (BMD) vary in their fracture risk,

290 Bone mineral elastic modulus was similar at 24 hours but

291 ivo observations support the hypothesis that bone mineral formation proceeds via disordered precursor

292 Here, a bone mineral inspired protein stabilization strategy is

293 Bone mineral is largely composed of hydroxyapatite (HA)

294 changes in (18)F-fluoride metabolic flux to bone mineral (K(i)) by PET/CT can provide incremental va

295 ctive protein, fibrinogen, and albumin), and bone mineral metabolism (25-hydroxyvitamin D, phosphorus

296 om the influences of the Fanconi syndrome on bone mineral metabolism.

297 s of grafting materials, including a natural bone mineral (NBM), demineralized freeze-dried bone allo

298 whereas the latter conferred a quasi-normal bone mineral phenotype through compensatory homeostatic

299 mechanical properties, rather than increased bone mineral turnover.

300 on; however, the use of deproteinized bovine bone mineral with 10% collagen (DBBM-C) in Piezocision f